Contest Trader

Don't miss the chance to cash-in prizes totaling

$10.000
Register here for the Ultimate demo trading competition

AstraZeneca and Johnson & Johnson to continue COVID-19 vaccine trials in the US

AstraZeneca and Johnson & Johnson to continue COVID-19 vaccine trials in the US

Two of the frontrunners in finding a viable medicine against COVID-19 are now able to resume their tests.

The week started with promising news from two of the companies that are working on a potential COVID-19 vaccine.

AstraZeneca and Johnson & Johnson announced that they are ready to resume the temporarily paused vaccine trials. The decision to halt the trails came after each of them reported that a volunteer got unexpectedly sick.

AstraZeneca was authorized by the US Food and Drug Administration to restart the trials after an inquiry showed that the global safety data showed that it's all safe. AstraZeneca's trial was held in September in the UK after a person developed a neurological condition.

Johnson & Johnson's trial was paused earlier this October after a participant reported an "unexpected illness." At the end of last week, JnJ stated that "no clear cause" led to the illness and that "preparations to resume the trial in the United States are now underway." No clear date was specified when the trial will resume, but according to people familiar with the matter, the event will probably occur next week.

According to government health officials and independent experts, these temporary pauses are setting an example of how safety processes work.

Following the news, AstraZeneca opened 0.87% higher, while Johnson & Johnson is at -0.03%.

Read more about JnJ's situation here!

Sources: edition.cnn.com, finance.yahoo.com

Esta información preparada por za.capex.com no es una oferta o solicitud con el propósito de comprar o vender ningún producto financiero referido en el presente o participar en una relación legal, ni un consejo o recomendación con respecto a tales productos financieros.

Esta información está preparada para su circulación general. No se refiere a ningún objetivo de inversión específico, situación financiera o necesidad particular de un receptor.

Debería evaluar independientemente cada producto financiero y considerar la idoneidad de dicho producto, teniendo en cuenta sus objetivos de inversión específicos, la situación financiera o las necesidades particulares, y consultar con un asesor financiero independiente si fuera necesario, antes de operar con los productos financieros mencionados en este documento.

Esta información no debe ser publicada, estar en circulación, reproducida o distribuida en su totalidad o en parte a ninguna persona sin el consentimiento previo por escrito de la Compañía.

El rendimiento pasado no es siempre indicativo de las probabilidades o del rendimiento futuro. Todos los puntos de vista y opiniones presentados son exclusivamente del autor y no representan necesariamente las de za.capex.com